Gillian Sanders Schmidler PhD

Gillian Schmidler

Leadership

Gillian Sanders Schmidler, PhD

Gillian Sanders Schmidler, PhD, is Professor of Population Health Sciences and Medicine at Duke University and Deputy Director of the Duke-Margolis Institute for Health Policy. Dr. Sanders Schmidler has a PhD in Medical Informatics from Stanford University and was an Assistant Professor of Medicine at Stanford’s Center for Primary Care and Outcomes Research from 1998 until the Fall of 2003 when she joined the faculty at Duke University. As the Duke-Margolis Deputy Director she oversees the Institute's educational, policy, and research missions. In addition to her leadership role within Duke-Margolis, she is core faculty within the Duke Clinical Research Institute. Dr. Sanders Schmidler’s research focuses on the development of evidence-based decision models to evaluate the comparative effectiveness of alternative prevention, treatment, and management strategies for chronic diseases – and the translation of such models into formats/tools that patients, healthcare providers, and policymakers can use in their decision-making process. Dr. Sanders Schmidler is Past President of the Society for Medical Decision Making (SMDM) and Director of Duke’s Evidence-based Practice Center (EPC) funded by the Agency for Healthcare Research and Quality (AHRQ) since 2009. She co-chaired the Second Panel on Cost Effectiveness in Health and Medicine. Dr. Sanders Schmidler has extensive research expertise in both methodology and application of comparative effectiveness and patient-centered outcomes research and leading collaborative investigator teams to perform successful and high-quality comparative effectiveness research.

Lowenstern A, Al-Khatib SM, Sharan L, Chatterjee R, Allen LaPointe NM, Shah B, et al. Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation: A Systematic Review. Ann Intern Med. 2018 Dec 4;169(11):774–87.

Borre ED, Goode A, Raitz G, Shah B, Lowenstern A, Chatterjee R, et al. Predicting Thromboembolic and Bleeding Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Systematic Review. Thromb Haemost. 2018 Dec;118(12):2171–87.

Neumann PJ, Kim DD, Trikalinos TA, Sculpher MJ, Salomon JA, Prosser LA, et al. Future Directions for Cost-effectiveness Analyses in Health and Medicine. Med Decis Making. 2018 Oct;38(7):767–77.